STEP Perspective Table of Contents, Spring 2003
From Seattle Treatment Education Project
-
A STEP Conference Review: 10th Conference on Retroviruses and Opportunistic Infections
By Lara Strick, M.D. and Jeffrey T. Schouten, M.D.
-
The 2NN Study
By Lara Strick, M.D.
-
Dear Healthcare Provider Letter From the Division of AIDS -- Concern About Trizivir Potency
By Jeffrey T. Schouten, M.D.
Advertisement
-
AIDS-Related Cancers: An Update
By Jeffrey T. Schouten, M.D.
-
Lipodystrophy and Metabolic Complications of HIV and Antiretroviral Therapies
By Benjamin Young, M.D., Ph.D.
-
The VaxGen Study
By Dennis Torres
-
Fuzeon (T-20), the First HIV Entry Inhibitor, Is Now FDA-Approved
By Jeffrey T. Schouten, M.D.
-
HIV Studies at Swedish Research Center
-
University of Washington ACTU Seeks Participants for Two New Studies
-
Ask Dr. Jeff
By Jeffrey T. Schouten, M.D.
|
|
Advertisement
|